Business
Medistim ASA - Share buyback program completed
Medistim ASA - Share buyback program completed
About this update from Medistim Asa
Oslo, 24h of April 2025: Reference is made to the stock exchange announcementmade by Medistim ASA on 11 March 2025 of the launch of Medistim's program torepurchase up to 70,000 of the Company's shares in open market transactionsfora total amount of up to NOK 35,000,000 during the period from 11 March 2025,until no later than 7 May 2025, pursuant to an agreement with DNB Markets. Forthe period from and including 11 March 2025, through 24th of April 2025, theCompany purchased a total of 70,000 shares at an average price of NOK 178.6328per share, all purchased as ordinary market purchases on Euronext Oslo Børs.Theshare buyback program is then completed. Please find below the lasttransactionoverview:-----------------------------------------------------------------------------Date / Aggregated daily volume (#shares) / Weighted average share price perday(NOK) / Total daily transaction value (NOK)Date: 22 April 2025. Number of share: 1,795. Avg price: NOK 162.9616 pershareDate: 23 April 2025. Number of share: 1,745. Avg price: NOK 159.9564 pershareTotal for this period:3,540 shares purchased at average share price of NOK 161.4590 per share. Totaltransaction value was NOK 571,639.99.Previously disclosed buybacks under the program:66,460 shares purchased at average share price of NOK 179.5465 per share.Totaltransaction value was NOK 11,932,661.75-----------------------------------------------------------------------------The issuer's holding of own shares: Following the completion of the above transactions, Medistim owns a total of93,117 of own shares (including 23,117 shares owned prior to the launch of thebuyback program), corresponding to 0.5078 % of Medistim's share capital.Appendix: An overview of all transactions made under the buyback program that have beencarried out during the above-mentioned time period is attached to this reportand available at www.newsweb.no.For further information, please contact:Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940Mail: [email protected] is information that Medistim is obliged to make public pursuant to the EUMarket Abuse Regulation and subject to the disclosure requirements pursuant toSection 5-12 of the Norwegian Securities Trading Act.https://newsweb.oslobors.no/message/644332